BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Ortho-McNeil Pharmaceutical, Inc. 



Raritan  New Jersey    U.S.A.
Phone: 800-682-6532 Fax:


SEARCH JOBS


Industry
Pharmaceutical






 Company News
Ortho-McNeil Pharmaceutical, Inc. Ditches $625 Million Diabetes Drug Pact with Diamyd Medical AB 6/2/2011 8:24:34 AM    More...
Ortho-McNeil Pharmaceutical, Inc. Enters into Agreement with Watson Laboratories, Inc. (WPI) for CONCERTA(R) Authorized Generic 11/2/2010 7:34:57 AM    More...
Metabolex, Inc. Enters Into Type 2 Diabetes Development and License Agreement with Ortho-McNeil Pharmaceutical, Inc.; Metabolex Could be Eligible to Receive Development, Regulatory, and Commercial Milestones up to $330 Million 6/22/2010 7:15:21 AM    More...
Ortho-McNeil Pharmaceutical, Inc. Pleads Guilty to Illegal Promotion of Topamax and is Sentenced to Criminal Fine of $6.14 Million 5/24/2010 8:05:57 AM    More...
Ortho-McNeil Pharmaceutical, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities 4/29/2010 11:39:29 AM    More...
FDA Issues Complete Response Letter for Ortho-McNeil Pharmaceutical, Inc.'s Rivaroxaban 5/28/2009 9:53:22 AM    More...
Ortho-McNeil Pharmaceutical, Inc. New Study Supports Use of LEVAQUIN as a Guideline-Concordant Antibiotic for the Treatment of Community-Acquired Pneumonia 10/27/2008 8:42:00 AM    More...
Isis Pharmaceuticals, Inc. (ISIS)Announces HSR Approval and Closure of Its Collaboration With Ortho-McNeil Pharmaceutical, Inc. 10/2/2007 10:33:00 AM    More...
FDA Approves Ortho-McNeil Pharmaceutical, Inc.'s LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis 9/17/2007 6:57:52 AM    More...
Isis Pharmaceuticals, Inc. (ISIS) Licenses Experimental Diabetes Drugs to Ortho-McNeil Pharmaceutical, Inc. for $45 Million 9/13/2007 7:08:45 AM    More...
123456789

//-->